Why Novanta’s latest earnings and guidance matter for investors
Novanta (NOVT) has become a focus for investors after reporting second quarter 2026 results that topped consensus estimates and pairing that with higher full year revenue and adjusted EPS guidance.
See our latest analysis for Novanta.
Novanta’s latest guidance and the contribution from the Riverpoint Medical acquisition come after mixed recent trading. The stock has posted a 37.77% year to date share price return but only a 3.40% total shareholder return over five years, which hints at strong recent momentum but a softer longer term picture.
If you are looking beyond Novanta for other potential ideas in medical technology and automation, this is a good moment to see what else is moving through our 36 robotics and automation stocks
The recent jump in Novanta’s share price sits between two possible readings. Either the higher guidance and Riverpoint Medical deal point to a stronger underlying business, or sentiment has run ahead of what the current fundamentals support.
Most popular narrative: 12.5% undervalued
The most followed narrative currently places Novanta’s fair value at $175, compared with a last close of $153.12. This implies a valuation gap that hinges on specific growth and margin assumptions.
The company's active pipeline of acquisitions, supported by a robust balance sheet and expanded credit, is positioned to steadily add new high-growth niches and lift recurring, software-heavy revenue. This approach is framed as a way to support long term revenue expansion and to smooth earnings, as more of the business ties to ongoing contracts and consumables rather than one off equipment sales.
Want to see what kind of revenue mix, margin profile and future earnings power that narrative leans on? The full story connects those moving parts to a higher long term valuation path for Novanta without assuming everything goes perfectly.
Result: Fair Value of $175 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Novanta narrative still hinges on smooth integration of Riverpoint Medical and on acquisitions picking up organic growth; any stumble on either front could quickly challenge it.
Find out about the key risks to this Novanta narrative.
Another view of Novanta’s valuation
The first narrative argues that Novanta is about 12.5% undervalued at $153.12 based on future earnings power. However, current P/E checks paint a different picture. The stock trades on about 107.6x earnings, while the fair ratio is 48.1x and the US Electronic industry average is 32.5x.
This is a large gap. It implies investors are already paying a premium to both peers and the fair ratio, which raises the bar for future execution and can limit room for error. The question is whether you see that premium as justified by Novanta’s earnings outlook or as a risk if expectations reset.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed signals around Novanta leave you undecided, this is a good time to review the details for yourself and move quickly to form your own view with the 1 key reward and 1 important warning sign
Looking for more investment ideas beyond Novanta?
If Novanta’s story has you thinking more broadly about your portfolio, this is the moment to widen your search and line up your next potential opportunities.
- Target potential mispricings by scanning focused opportunities through the 51 high quality undervalued stocks that fit strict quality and fundamentals filters.
- Build a steadier portfolio foundation by reviewing the solid balance sheet and fundamentals stocks screener (50 results) that can better handle tougher conditions.
- Get ahead of the crowd by searching through a screener containing 17 high quality undiscovered gems before they appear on everyone else’s radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com